SCHEMBL5653620

SCHEMBL5653620

Nc1ncc(CNC(=O)O)s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.53
TSHR P16473 2/20 0.46
POLB P06746 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42
HSD17B10 Q99714 2/20 0.42
THRB P10828 1/20 0.42
HTT P42858 1/20 0.42
RECQL P46063 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
F2 P00734 1/20 0.42
HRH2 P25021 5/20 0.42
EPHX2 P34913 1/20 0.41
NOS1 P29475 1/20 0.41
CSNK2A1 P68400 1/20 0.40
HDAC6 Q9UBN7 1/20 0.39
DRD2 P14416 1/20 0.39
HRH1 P35367 1/20 0.39
DRD3 P35462 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21229056 0.83 NAMPT (0.38) SMN1; SMN2TSHRHDAC6CYP1A2CYP2D6
SCHEMBL5684644 0.82 SMN1; SMN2 (0.50) SMN1; SMN2TSHRPOLBALDH1A1MAPT
SCHEMBL290401 0.81 FPR2 (0.44) SMN1; SMN2TSHRHTTF2HDAC6
SCHEMBL20659199 0.81 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1MAPTRECQLL3MBTL1
SCHEMBL21229048 0.79 HDAC1 (0.49) HDAC6
SCHEMBL6865101 0.78 SMN1; SMN2 (0.41) SMN1; SMN2TSHRPOLBALDH1A1MAPT
SCHEMBL3255716 0.77 SMN1; SMN2 (0.60) SMN1; SMN2TSHRPOLBALDH1A1MAPT
SCHEMBL18381560 0.76 SMN1; SMN2 (0.48) SMN1; SMN2TSHRPOLBL3MBTL1KDM4E
Bromide SCHEMBL5048845 0.76 SMN1; SMN2 (0.58) SMN1; SMN2TSHRPOLBALDH1A1MAPT
SCHEMBL21229053 0.75 HDAC1 (0.51) SMN1; SMN2ALDH1A1MAPTHDAC6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070105908-A1 Thiazolimine compound and oxazolimine compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-05-10 US disclosed
EP-1640369-A1 THIAZOLIMINE COMPOUND AND OXAZOLIMINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-03-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105908-A1 Thiazolimine compound and oxazolimine compound CMA1, TH, NPR3 SMN1; SMN2 3302/4885TSHR 724/4885POLB 3772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.